Analysis of the Internal Environment of the Pharmaceutical Distributor Operation in Russia Using SWOT Analysis by Krylova, O. et al.
382 https://www.id-press.eu/mjms/index
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Sep 10; 8(E):382-388.
https://doi.org/10.3889/oamjms.2020.3628
eISSN: 1857-9655
Category: E - Public Health
Section: Public Health Legislation
Analysis of the Internal Environment of the Pharmaceutical 
Distributor Operation in Russia Using SWOT Analysis
O. V. Krylova*, T. M. Litvinova, L. I. Babaskina, D. V. Babaskin, O. V. Savinova
Department of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russia
Abstract
BACKGROUND: The general directions of the organization’s development should be clearly formulated, i.e., 
a business strategy should be developed in order to achieve the long-term competitive advantages in the operation 
of a pharmaceutical distributor with its own pharmacy warehouse in Russia.
AIM: Identification of strengths and weaknesses, opportunities and threats in the operation of a pharmaceutical 
distributor with its own pharmacy warehouse.
MATERIALS AND METHODS: The SWOT analysis was used to analyze the environment, which enabled a joint 
study of the external and internal environment. During the study, content analysis of secondary sources of information 
was used (data from the Federal State Statistics Service, DSM Group marketing agency), as well as sociological 
analysis.
RESULTS AND DISCUSSION: During the SWOT analysis, ten factors were identified that ensured the normal 
functioning of the pharmaceutical distributor, as well as 11 negative factors were identified that negatively affected the 
operation of the pharmacy warehouse. The article presents qualitative description of the strengths and weaknesses. 
Ten factors were attributed to the favorable opportunities for the organization’s activities; seven positions were 
considered as threats to the activities of the distributor. It should be noted that all factors of external environment are 
in a state of strong mutual influence. A change in one of the factors necessarily leads to a change in other factors. 
Therefore, their study and analysis should not be carried out separately, but systematically, with tracking not only 
the actual changes in one factor but also the process how these changes will affect other factors. After identifying 
strengths and weaknesses, opportunities and threats, a table was compiled and all intersections were analyzed, i.e., 
all possible pairwise combinations that would help determining the future strategy. At present, the strategic goal of a 
number of wholesale companies in the pharmaceutical market is defined as increasing return on investment.
CONCLUSION: In this article, SWOT analysis has been used to provide some suggestions on overcoming 
weaknesses and threats in the activities of a pharmaceutical distributor, as well as on proper use of strengths and 
opportunities. During the study, pharmaceutical industry practitioners discussed the impact of various economic 
factors, strengths, opportunities, weaknesses, and threats regarding the activities of pharmaceutical distributor, as 
well as related problems and prospects for the future.
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Introduction
The drug distribution market in Russia is 
undergoing major changes due to the creation of a 
single market within the EAEU, the introduction of the 
law on the mandatory labeling of drugs, and the import 
substitution policy under the “Pharma 2030” strategy [1]. 
Consequently, a marketing analysis is required of both 
the external market situation and internal resources 
for the implementation of strategic planning [2], 
[3], [4], [5], [6], [7], [8], [9], [10], [11]. Many authors 
[12], [13], [14], [15], [16], [17], [18], [19], [20], [21] use 
SWOT analysis as the main tool for managing the 
organization, since this method allows simultaneously 
analyzing the internal factors of the company (strengths 
and weaknesses) and external ones (threats and 
opportunities), and identifying the relationship 
between them, which will allow the organization 
to obtain a structured description of the current 
situation and determine appropriate development 
tactics [22], [23], [24], [25], [26], [27], [28].
A large sector in the pharmaceutical distributor 
market is occupied by pharmaceutical companies 
with their own pharmacy warehouse [29]. The internal 
structure of such organizations has certain specifics, 
which has its advantages and disadvantages. Therefore, 
it is necessary to highlight the universal parameters 
of the organization and the external environment that 
can be effectively applied in a SWOT analysis, which 
will allow any company of this type to assess whether 
its strengths are used as an advantage, whether its 
weaknesses are compensated, and also determine 
favorable circumstances for growth and primary threats.
Thus, the study is aimed at identification of 
strengths and weaknesses, opportunities and threats in 
the activities of a pharmaceutical distributor with its own 
pharmacy warehouse.
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Materials and Methods
To analyze the environment, the method of 
SWOT analysis was used during which a qualitative 
analysis of the internal factors characteristic of the 
pharmaceutical distributor with a pharmacy warehouse 
and their relationship with the external environment 
was carried out.
Strengths and weaknesses of the 
organization, opportunities and threats were identified 
by representatives of pharmacy warehouses. A 
wide range of factors was considered as an internal 
environment, including an analysis of personnel, 
facilities, equipment, and the organization’s pricing 
policy. The external environment was studied from the 
perspective of developing and changing the structure 
of the pharmaceutical market, regulatory regulation, 
government support measures, and the socio-economic 
situation in the country.
Further, these parameters were compared by 
compiling a matrix. Its quadrants indicated the forces 
that allowed using the opportunities with the greatest 
benefit; forces that allowed effectively countering threats; 
weaknesses that limited the company’s capabilities in 
the external environment; and weaknesses that carried 
high risks for the enterprise.
Based on the matrix obtained, recommendations 
were proposed for adjusting the weaknesses of the 
enterprise and countering the threats in the external 
market [22].
Results and Discussion
Let us consider the characteristic features 
of strengths and weaknesses of the operation of 
a pharmaceutical distributor with its own pharmacy 
warehouse. Strengths can be represented by the 
following indicators:
•	 S1. Company with a long record. A long record 
secures recognition and customer confidence.
•	 S2. Wide range in the price list and its constant 
expansion. Availability of a wide range of items 
in the price list allows attracting new customers 
and provides a wide selection for the existing 
customers.
•	 S3. High wages. Higher wages in comparison 
with other organizations involved in 
pharmaceutical activities motivate employees 
of all levels to perform their duties better and 
eliminates the “staff turnover” typical of many 
Russian organizations.
•	 S4. Own premises of the pharmacy warehouse. 
It reduces the company’s rental costs, which 
allows using the saved assets in other areas of 
development.
•	 S5. Validation of warehouse processes. 
Warehouse thermal mapping. In practice, 
validation consists in testing the ability of certain 
engineering equipment in the warehouse 
(ventilation system, refrigeration units, etc.) 
to perform its functions in order to maintain 
storage conditions within acceptable limits. In 
turn, thermal mapping allows to determine such 
important factors as the location of the most 
critical areas of the space, subject to frequent 
temperature fluctuations due to the space 
structure and other factors, as well as to identify 
the most stable temperature zones of the 
warehouse, where it is recommended to store 
goods and place racks in accordance with the 
requirements for the products storage mode.
•	 S6. Availability of the own pharmacy 
network. This indicator makes the company 
more stable and more competitive in the 
pharmaceutical market. Ten of the top ten 
distributors own one or more pharmacy 
chains. The development of own pharmacy 
chains provides an increase in sales 
channels and cost control; strengthening 
of regional presence and access to various 
price segments; and acquisition of partners in 
the retail market and capacity utilization [1].
•	 S7. Availability of direct long-term contracts 
with domestic producers. It allows purchasing 
domestic drugs directly from producers, 
bypassing the extra links of the distribution 
chain. As a result, a competitive price can be 
offered in the market, and the maximum benefit 
from the sale can be obtained.
•	 S8. Flexible pricing. Non-linear pricing allows 
adapting to a wide variety of customers: Both 
large wholesalers and small retail customers.
•	 S9. Relatively low retail prices. In most cases, 
flexible pricing allows setting the price to include 
each group of customers in a competitive 
range (usually in the top five by price).
•	 S10. Flexible system of arranging work with 
customers and suppliers. It allows optimizing 
the work process as much as possible, adapting 
to the partner and beginning cooperation 
immediately.
Let us analyze possible weaknesses of the 
organization engaged in pharmaceutical activities.
•	 W1. High costs of manual labor at the 
warehouse. Lack of the automatic assembly 
necessitates a large staff, and, as a result, 
additional units should be formed to control the 
ever-increasing number of employees.
•	 W2. Lack of specialists in the pharmaceutical 
warehouse validation. Without observing the 
drugs storage and transportation conditions, 
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there can be no confidence in the quality, 
safety, and effectiveness of drugs.
•	 W3. Significant load on a manager. The need to 
perform work beyond one’s competence leads 
to a deterioration in the quality of immediate 
duties.
•	 W4. Lack of foreign economic activities. A 
sufficiently large number of domestic products 
are exported to the CIS countries and other 
developing countries that do not have their 
own high-quality pharmaceutical production. 
The lack of the foreign economic activities 
means the loss of customers settling in a stable 
international currency, as well as the loss of 
customers – major players in the domestic 
market of the importing country.
•	 W5. No branches in other cities. There are also 
big losses of customers: Pharmacy chains, 
small- and medium-sized wholesalers located 
in other regions of the country, which cannot 
afford additional cost of transportation from 
the central region of the country to the local 
market.
•	 W6. Too many top managers. Due to the growing 
administrative dimension of the company, there 
can be one subordinate per manager.
•	 W7. Lack of analytical and marketing 
departments. The procurement department 
takes over the function of marketing and 
market analysis in many pharmaceutical 
organizations. As a result, as the range of 
positions grows, managers perform triple work 
and do not always cope with it because of the 
increased duties and responsibilities.
•	 W8. Lack of career growth. A situation when 
fairly strict work requirements are presented to 
a new employee has arisen in many companies. 
If the employee is doing well, the company 
appreciates their work and initiatives, but further 
career growth stops, as the employee is no 
longer considered for another, higher position. 
The employee is doing his job very well, but his 
promotion is a risk: Whether he will cope with 
new responsibilities, and whether a competent 
employee will replace him.
•	 W9. High and ever-increasing receivables. 
Due to the unstable situation in the country’s 
economy, many customers fail and declare 
themselves bankrupt, or continue operating 
but do not cope with the accumulated debts.
•	 W10. Lack of direct contracts with well-known 
foreign drug producers. No direct contracts 
with producers force the company to purchase 
their drugs from third parties, sometimes 
through many intermediaries, which increases 
the price while reducing competitiveness and 
the company’s profit.
•	 W11. Underdeveloped marketing information 
system. This problem is common to the entire 
pharmaceutical market. If large distributors 
cope with this problem, all their positive results 
are leveled with the inability to resolve this 
problem with their partners for various reasons. 
Moreover, due to high competition, companies 
are not always eager to share information 
with their partners. As such, the burden of the 
obligation to provide marketing information 
often rests with the very first links in the trade 
chain – producers.
Let us consider the opportunities of the 
pharmaceutical distributor with its own pharmacy 
warehouse.
•	 O1. Increasing number of domestic drugs. The 
development of the domestic pharmaceutical 
industry has been a priority socioeconomic 
task of the state since the introduction of import 
substitution [3].
•	 O2. High growth of the pharmaceutical market. 
The pharmaceutical market is a dynamically 
developing sector of the global economy. 
According to the data of the Monthly Retail 
Audit of the Russian Pharmaceutical Market 
conducted by DSM Group marketing agency, 
5.3 bln packages of drugs worth about 991.9 
bln rubles (in retail prices) were sold through 
pharmacies in 2018. The drug sales grew by 
4.6% in value and 4.9% in kind compared to 
2017 [4].
•	 O3. Organization of auctions for procurement 
of drugs funded from the budget. The state 
is the largest and most stable player in the 
pharmaceutical market – therefore, cooperation 
with state agencies is a 100% guarantee of the 
return on procurement funds.
•	 O4. Growing number of pharmacies, 
drugstores, and kiosks. Increasing number of 
potential customers. According to experts, the 
number of drugstores in Russia has grown 
by 175% over the past 3 years. In particular, 
according to statistical indicators, there is 
one pharmacy per 1800 inhabitants [30]. 
This indicator influences the number of 
potential customers for the operation of the 
pharmaceutical distributor under study.
•	 O5. Decrease in the number of competitors 
due to the unstable economic situation. As 
mentioned above, not all companies are 
able to withstand competition in the current 
economic situation. The decreasing number 
of competitors provides an opportunity to 
occupy their niche in the market or to allow 
own customers to occupy it, thereby indirectly 
boosting the company’s profit.
•	 O6. Poor policy of competitors. Like withdrawal 
from the market, the poor policy of competitors 
enables the company to occupy new niches 
and attract new customers, thereby increasing 
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its market share. It is important that the wrong 
behavior is much more common than a 
decrease in the number of competitors, but at 
the same time, the share of the increase in its 
influence is less.
•	 O7. Including new types of products and 
expanding the range. With a constantly 
evolving market and the appearance of new 
types of products, it is important to respond 
in time, correctly evaluate, and possibly 
introduce new products to the market, if they 
are cost-effective.
•	 O8. Minimizing stock by pharmacies. It is a 
very important factor: Due to constant price 
fluctuations, retail, and wholesale customers 
try minimizing the product balance, thus 
increasing the frequency of purchases, which, 
with the right pricing policy, and brings regular 
loyal customers.
•	 O9. Development of information technology. 
The company is able to achieve significant 
saving having correctly and timely introduced 
information technology into its operations. 
Unfortunately, it is often necessary to 
instantly invest a tangible amount of money to 
implement a new technology, and it is important 
to estimate the benefits for the company from 
this investment in the future.
•	 O10. Development and improvement of 
automated accounting systems. The growth of 
the company, opening of new pharmacies and 
new departments, as well as increases in stock 
and sales all contribute to the increase in the 
array of information that needs to be constantly 
processed. The introduction of an automated 
accounting system and, just as importantly, 
its correct setup and proper use can save a 
company a considerable amount of money.
The next stage of our study is the identification 
of threats to the operation of the pharmaceutical 
distributor with its own pharmacy warehouse.
•	 T1. Instability of the national currency. The 
company may go bankrupt if it fails to predict 
the changes in the national currency rate in time 
and take appropriate measures (producers 
usually import substances and therefore settle 
in foreign currency).
•	 T2. Inflation development. A high inflation rate 
(in 2019, inflation [3%] took second place in 
the entire history of observations, it was lower 
only in 2017 – 2.5%; in 2018, inflation was 
4.3% [31]) primarily impacts the bank rate – 
its appreciation means an increase in the loan 
interest rate, and, consequently, an increase in 
the cost of products for the customer in the long 
term. Most large customers “force” suppliers to 
provide them with a deferment (according to 
the Pareto rule, such customers are the most 
profitable), and sales volume decreases due to 
price increases – as a result, the company’s 
profit falls.
•	 T3. Acute competition. The pharmaceutical 
market has always existed in the conditions 
of fierce competition of its players. However, 
competition for the vacated space only 
intensifies after the withdrawal of players from 
the market, which are often very large. According 
to the DSM Group marketing agency, in 2018, 
the number of pharmaceutical distributors 
in the Russian market was more than 400, with 
the exception for microenterprises [1].
•	 T4. Delays in financing budget organizations. 
This unpleasant situation can turn out very 
painful for the company due to the delay in 
financing state-owned enterprises during the 
crisis. As a result, payment for supplies to a 
state-owned institution will be refunded, but 
due to delays in financing and the above-
mentioned fluctuations in the national currency 
and inflation, the company will lose in value 
while receiving full payment in quantitative 
terms.
•	 T5. Insolvency of some retail customers. 
This problem for the company originates not 
from the beginning of the trade link but from 
its end. Commercial retail organizations are 
the second last link of the entire trade chain, 
and this is the majority of consumers in the 
country. Their insolvency will eventually affect 
the distributor.
•	 T6. Unemployment growth. In September 
2018, unemployment rate amounted to 
4.5%. As a result of Federal State Statistics 
Service [31], welfare per capita falls, and the 
purchasing power of the population declines.
•	 T7. Change in prices. This criterion is closely 
related to the stability of the national currency. 
A sharp fall in prices for products will lead to 
stagnation of products in the warehouse until 
the previous cheap consignments of products 
and their analogues are “washed out” from 
the market, which increases the cost of their 
logistics and storage.
Let us build a matrix of the qualitative SWOT 
analysis following the identification of strengths and 
weaknesses, opportunities and threats to the operation 
of the pharmaceutical distributor with its own pharmacy 
warehouse (Table 1).
Discussion
An analysis of the internal potential of a 
pharmaceutical company makes it possible to determine 
its strengths and weaknesses in business, to assess 
their relationship with external factors.
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Table 1: Matrix of the qualitative SWOT analysis
Opportunities Threats
Strengths S1-O3; S1-O4; S1-O5; S1- O6;
S2- O7;
S3-O5;
S4-O3;
S5-O3; S5-O7; S5-O8;
S6-O1; S6-O7; S6-O8;
S7-O1; S7-O2; S7-O3; S7-O9;
S8-O2; S8-O3; S8-O4; S8-O9;
S9-O1; S9-O2; S9-O3; S9-O4; 
S9-O6; S9-O7;
S10-O9; S10-O10
S1-T3;
S2-T2; S2-T5; S2-T7;
S3-T6;
S4-T1; S4-T2;
S5-T1; S5-T2;
S6-T3; S6-T5;
S7-T3;
S8-T3;
S9-T1; S9-T2; S9-T3; S9-T4;
S10-T1; S10-T2; S10-T3; S10-T4; 
S10-T7
Weaknesses W1-O9; W1-O10;
W2-O8;
W3-O9; W3-O10;
W4-O5; W4-O6; W5-O5; W5-O6;
W6-O1; W6-O2; W6-O4; W6-O7;
W7-O5; W7-O6; W7-O9; W7-O10;
W8-O2;
W9-O2;
W10-O3; W10-O9; W10-O10;
W11-O9; W11-O10
W1-T3 W2-T3 W3-T3 W4-T1 W4-T2 
W5-T1 W5-T2 W6-T1 W6-T2 W7-T3 
W8-T3 W8-T6 W9-T4 W9-T5 W9-T7 
W10-T3 W10-T7 W11-T3
The strengths of the organization engaged 
in pharmaceutical activities are the advantages 
and benefits that distinguish the company from 
its competitors. Weaknesses are the enterprise’s 
shortcomings that need to be fixed so that competitors 
cannot use them as their advantages.
The main task of the external analysis is to 
identify and understand the opportunities and threats 
that may occur for the considered organization in 
the present or arise in the future. Opportunities of 
the organization are positive factors (trends and 
phenomena) of the external environment, which can 
lead to an increase in sales and profits. Threats are 
negative factors (trends and phenomena) of the external 
environment, which can lead to a significant decrease 
in sales and profits in the absence of an appropriate 
reaction of the organization.
The ultimate goal of external analysis is 
the formation of alternative strategic decisions, 
their assessment and the final choice of 
strategy [30], [31], [32], [33], [34], [35], [36], [37], [38]. 
These decisions should be focused on the use of 
opportunities and protection against threats associated 
with changes in the external environment.
The decision matrix is the result of SWOT 
analysis that allows developing and taking decisions that 
can help using the identified opportunities and neutralize 
threats [12],[13], [14], [15], [16], [17], [18], [19], [20], [21].
The “Strengths – Opportunities” field reflects 
the use of the company’s strengths to get a return on 
opportunities. This field presents options of company 
development strategies.
The “Strengths – Threats” field shows which 
strengths of the company can be used to eliminate 
identified threats.
The “Weaknesses – Opportunities” field 
allows identifying ways to overcome the company’s 
weaknesses by implementing external opportunities.
The “Weaknesses – Threats” field reflects 
strategic initiatives, namely, the need to minimize 
the company’s weaknesses to avoid threats from the 
external environment.
Based on the results of the analysis, strengths 
and weaknesses, as well as opportunities and threats to 
the pharmaceutical distributor can be compiled. Thus, a 
complete picture of the SWOT analysis is provided.
Let us analyze the relationship of the above-
indicated factors with the external environment. First, 
we consider the possible strengths of the company and 
determine the tactics of their use in the pharmaceutical 
market.
One of the significant advantages of the 
company is its long history as this determines company 
vision and inspires confidence in it. In connection with 
the current policy of import substitution, the growth of 
the retail sector of the pharmaceutical industry, this 
fact allows easier and faster establishing partnerships 
with the other market players. This will reduce the 
threat of competition, especially against the backdrop 
of the current economic situation, as weak wholesale 
organizations depart from the industry due to their 
incorrect policies.
One of the tactics of market development is 
to expand the assortment of the company. However, 
when implementing such a strategy, it is necessary to 
conduct full risk-benefit assessment since this implies 
serious economic threats due to the observed inflation, 
insolvency of retail customers, change in the price level 
of the manufacturer caused by the import of most of the 
substances.
High wages will be an indisputable advantage 
of the organization in the labor market; however, due to 
an unstable economy, an analysis of the feasibility and 
ability of the company to maintain it at a sufficiently high 
level is necessary.
The advantage will be the ownership of a 
pharmacy warehouse that complies with all GDP 
standards, i.e., it has been validated and thermomapped, 
as this provides advantages both in organizing tenders 
at the expense of budget funds and in issuing state 
benefits and subsidies.
Own pharmacy network is available only to 
large market players due to high economic costs but 
this gives them advantages in marketing products, the 
ability to minimize their own inventories.
A fundamental fact will be the long-term 
contracts with suppliers of goods. This guarantees to 
company continuous supply and helps to survive in a 
competitive environment.
A similar approach should be developed for 
customers; the main methods for achieving this goal 
will be flexible pricing policy and relatively low selling 
prices.
The above factors will be achievable with the 
flexible system for setting up work with customers and 
suppliers. The current level of information technology 
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development, design, and improvement of automated 
accounting systems allows effectively implementing this.
Thus, if the company is characterized by most 
of the above factors, such threats as competition in 
the pharmaceutical market, instability of the national 
currency, retail insolvency, price increases, and high 
unemployment rates can be reduced.
Let us analyze significant shortcomings of the 
organization, the risks associated with them, and the 
possibilities for eliminating them.
A significant problem for the company 
is personnel problems such as lack of validation 
specialists, high manual labor costs at the warehouse, 
and significant burden on one manager. This carries 
threats associated with increased competition. However, 
the lack of qualified personnel can be reduced by 
introducing automated accounting systems and other 
information technologies.
Organizations should also pay attention to 
expanding the geography of their activities since lack 
of foreign economic activity and branches in other cities 
reduce the company’s opportunities. In an unstable 
economy, with the observed decrease in the number of 
competitors, company possessing necessary resources 
should react quickly.
In the conditions of a dynamically changing market, 
it is necessary to constantly evaluate the organization’s 
personnel policy with a view to optimizing it, identifying 
personnel reserve and rotating staff. Often there is an 
excess of managerial staff and the absence of marketing 
and analytic departments, which entails lack of strategic 
planning and insufficient development of the marketing 
information system. The latter affects the presence of 
contacts with well-known foreign manufacturers of drugs; 
therefore, the company loses profit.
Due to rising prices from suppliers, delays in 
financing of budgetary organizations and insolvency of 
the retail chain, a company may have serious problems 
with high and constantly growing level of receivables.
Thus, the above-indicated internal factors 
reduce the opportunities for company development 
and expose it to threats from competitors, inflation, 
and constant increase in the level of prices for drugs. 
However, there are opportunities to reduce them, such 
as the dynamic growth of the national pharmaceutical 
market, government policies to reduce the import of 
drugs, and the development of information technology 
and automation capabilities.
Conclusion
The main goal of this study was to identify the 
strengths and weaknesses, opportunities, and threats 
in the operation of a pharmaceutical distributor with its 
own pharmacy warehouse for drugs and pharmacy-
sold products. The possible weaknesses and strengths 
of the pharmaceutical organization have been identified 
using the SWOT analysis, with a particular attention paid 
to the analysis of the weaknesses that can be turned 
into strategies to increase the company’s advantages 
in the market. The opportunities and threats that the 
pharmaceutical business may face were described 
next.
As such, the analysis of the obtained 
information and the quality of the decision made 
directly depend on the completeness and reliability of 
the collected information and the correct use of the 
methods and techniques for analyzing this information. 
Identification of weaknesses and threats, as well as their 
compensation with strengths and opportunities will lead 
to an increase in the profitability of a pharmaceutical 
distributor if it seeks to develop its activities, expand 
its markets, increase its product range, improve 
technologies, and thus increase sales and profits.
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